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ABSTRACT 
Translational research in medicine aims to inform the clinic and the laboratory with the results of each other’s work, 
and to bring promising and validated new therapies into clinical application. While laudable in intent, this is complicated 
in practice and the current state of translational research in cancer shows both striking success stories and examples of 
the numerous potential obstacles as well as opportunities for delays and errors in translation. This paper reviews the 
premises, promises, and problems of translational research with a focus on radiation oncology and suggests opportunities 
for improvements in future research design. © 2008 Biomedical Imaging and Intervention Journal. All rights reserved. 
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"A good many times I have been present at 
gatherings of people who, by the standards of 
the traditional culture, are thought highly 
educated and who have with considerable gusto 
been expressing their incredulity of scientists. 
Once or twice I have been provoked and have 
asked the company how many of them could 
describe the Second Law of Thermodynamics. 
The response was cold: it was also negative. 
Yet I was asking something which is the 
scientific equivalent of: Have you read a work 
of Shakespeare's?  
I now believe that if I had asked an even 
simpler question -- such as, What do you mean 
by mass, or acceleration, which is the scientific 
equivalent of saying, Can you read? -- not more 
than one in ten of the highly educated would 
have felt that I was speaking the same language. 
So the great edifice of modern physics goes up, 
and the majority of the cleverest people in the 
western world have about as much insight into 
it as their neolithic ancestors would have had."  
  – CP Snow The Two Cultures (1959) 
 
“Traddutore, traditore”  
– Italian Proverb, loosely translated as  
‘To translate is to betray.” 
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‘Translation is the action of interpretation of 
the meaning of a text, and subsequent 
production of an equivalent text, also called a 
translation, that communicates the same 
message in another language.’  
– Wikipedia accessed 1 September 2008. 
INTRODUCTION 
Twenty-five years ago when I was completing my 
Fellowship in Radiation Oncology there was little use of 
the term ‘translational research’, in cancer or elsewhere 
in medicine. There were clinicians and there were 
laboratory scientists. They kept different hours (6AM to 
6PM for the clinicians, noon to midnight for the basic 
scientists). They tended to differ in age, dress, style of 
music, and a host of other superficialities. To some 
degree they represented two tribes within the common 
culture of science. While not yet speaking the different 
languages that Snow cites, they were clearly using quite 
different dialects. 
But even then some saw the need to bring these two 
groups together in the service of a goal more exciting 
and more important what either could do alone. One of 
my first mentors combined a full time cardiology 
practice with running an immunology lab, which resulted 
in the development of diagnostic and therapeutic 
antibodies against cardiac glycosides [1]. During my 
Residency in Radiation Oncology at Tufts-New England 
Medical Center Hospital, we had a tradition that 
Radiation Physicists and Radiation Biologists would 
routinely attend our daily new patient presentation 
conference. Their questions, often unencumbered by the 
then current clinical dogmas, sometimes seemed to come 
out of left field, but perhaps that is where the best 
answers are to be found. 
Translational research has now become somewhat of 
a buzzword in medicine, along with such concepts as 
‘molecular medicine’ and ‘personalised medicine’. This 
is all to the good of medicine. The close intermingling of 
theory and practice, in vitro and animal models with the 
human reality of clinical practice, has brought significant 
advances both in our basic understanding of the biology 
of human cancer and in its treatment. Yet general 
acceptance of the concept does not mean that its 
implementation is either widespread or easy. And 
contrary to the simplistic “Bench to Bedside” slogan that 
we use to drum up support for translational research, in 
practice it is a complex dance from bench to bedside and 
back again, repeatedly, with not only the clinician and 
basic scientist as dancers but with the active (for good or 
bad) involvement of academic, governmental, and 
commercial onlookers and regulators. Recently the 
United States National Cancer Institute has created a 
Translational Research Working Group (TRWG) 
specifically charged with defining and improving the 
processes by which new compounds and/or devices are 
brought from initial conception or discovery to the point 
of clinical evaluation in patients [2]. The general 
overview of this process, as well as specific 
considerations apropos to the development of drugs for 
medical oncology and devices for radiation oncology, 
have been recently published [3-5]. In this article I will 
review some of the premises, explicit and implicit, that 
underlie the concept of translational research, give some 
examples of successful and unsuccessful attempts at their 
implementation, and address structural impediments and 
possible solutions. The high cost and relative 
inefficiency of the development of new treatments in 
oncology, with only a small portion of promising new 
therapies proving superior to established ones, mandates 
a review of our clinical research practices [6-8]. If the 
focus seems at times negative, this is not because I think 
that translational research is a failure, which I 
emphatically do not, but because I think that we often 
learn more from an analysis of our failures than a 
celebration of our successes. 
Principles of translational research 
A core premise of translational research, whether in 
oncology or other disciplines, is that clinical trials are 
more likely to advance knowledge and lead to improved 
treatment when they are done in close collaboration with 
basic science. Trials should not simply compare clinical 
endpoints, such as survival, for patients given ‘Treatment 
A vs. Treatment B’ but also provide information which 
will allow testing of the proposed underlying 
mechanisms behind the two treatments. This will 
typically entail inclusion of some, if not all, of the 
following features: 
●  Design of clinical trials is based on laboratory 
observations regarding tumour biology and 
agents which may be able to perturb it. 
●  Intermediate endpoints which may address the 
clinical hypothesis being tested whether or not 
the primary endpoint is satisfied. 
●  Collection of data on additional endpoints (e.g. 
quality of life, economic impact on patients and 
caregivers). 
●  Collection of biologic specimens (tumour, 
normal tissue, blood, urine) for studies 
correlating DNA, RNA, protein, and drug 
metabolite information with clinical outcomes 
in this trial and hypothesis generation for later 
studies.  
●  Feedback of outcome data (e.g. local control, 
survival, patterns of failure) to basic scientists 
for evaluation of original study hypothesis and 
generation of new hypotheses and agents with 
which to test them. 
In practice these criteria are fully met in only a 
minority of trials. Limitations in our understanding or the 
mechanisms of actions of agents, particularly ‘off-target’ 
effects, cost and difficulty of obtaining tissue specimens 
from patients, especially those with solid tumours – with 
which to make the desired correlations between 
administered agent, molecular effects in target tissues, 
and clinical outcomes, as well as commercial and H Wagner Jr. Biomed Imaging Interv J 2008; 4(3):e47   3 
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academic pressures to succeed quickly – have all 
distorted the idealised research process. As it is currently 
practised, translational research is often too slow and 
ineffective in developing successful new therapies [9-10]. 
Some Examples 
The development of agents which can interfere with 
signaling pathways mediated through the epidermoid 
growth factor receptor (EGFR) signal pathway provides 
a good example of the translational research approach, 
including its successes, failures, and surprises. Over the 
past three decades, the existence of this pathway has 
been recognised , leading to description of its 
significance to tumour growth and frequent correlation of 
its activity with resistance of tumours to treatment such 
as radiotherapy, the development of several classes of 
agents including monoclonal antibodies directed against 
the receptor (e.g. Cetuximab) and low molecular 
compounds (TKI) which target the ATP binding site in 
the intramolecular kinase domain of the receptor , and 
the completion of clinical trials evaluating several of 
these either as single agents or in combination with 
radiation therapy or chemotherapy [11-15]. The result of 
this effort has been both the approval of several agents 
for clinical use and marked increase in our understanding 
of the biology of this signaling pathway and its 
perturbation in a variety of tumours. The observation that 
some groups of patients (such as nonsmoking Asian 
women with adenocarcinoma of the lung) had very high 
response rates to TKI led to the discovery of activating 
mutations in the kinase domain of the EGFR and a much 
better appreciation of the molecular heterogeneity of the 
family of diseases we call lung cancer. While this has 
been a translational success story in many respects, key 
elements have been frustratingly incomplete or absent. 
Despite the early interest in EGFR inhibition as a 
strategy for radiosensitisation, only one Phase III trial 
with Cetuximab in head and neck cancer has been 
completed and published. Several small Phase II trials 
with Cetuximab and chemoradiation have been reported 
in non-small cell lung cancer (NSCLC) and have led to a 
currently active RTOG Phase III trial. Correlation 
between either overexpression or mutation of the EGFR 
in subjects on these trials has been largely lacking. Even 
in the much larger trials looking at either Cetuximab or 
the TKI Gefitinib or Erlotinib in NSCLC, the lack of 
assay standardisation has left us with a somewhat 
confusing picture regarding the relative importance of 
mutations (which seek key for single agent activity of the 
TKI in NSCLC) versus overexpression of EGFR which 
may be sufficient for radiosensitisation. The relative lack 
of clinical success of the TKI as radiosensitisers is 
surprising in view of their in vitro activity, and it is only 
recently that we are beginning to recognise that while 
both antibodies such as Cetuximab and TKI will block 
EGFR mediated cell signaling, they do so via profoundly 
different ways with markedly different downstream 
effects. Such facets of EGFR activity as its nuclear 
localisation were unknown when these agents were 
developed, and the feedback from the clinic to the 
laboratory that has occurred with the results of first 
generation trials has greatly enhanced our understanding 
of EGFR biology. 
Inhibition of farnesyltransferase and ras 
At about the same time that the EGFR story was 
developing, it was recognised that mutational activation 
of the ras protein was a major feature of a variety of 
malignancies. It was also observed that increased ras 
signaling was associated with radiation resistance in 
several cell lines [16]. As is often the case, this was first 
thought to be a simple phenomenon, and the importance 
of the various members of the ras protein family 
underappreciated. With the realisation that, for ras to 
play its role in cell signaling it required post-translational 
modification including attachment of a prenyl group to 
allow its incorporation into lipid membranes, the search 
was on for a selective inhibitor of the enzyme thought to 
be most responsible for this, ras farnesyltransferase 
(FTase). A number of compounds of varying structures 
were developed which were active FTase inhibitors and 
which showed impressive clinical activity against tumour 
lines harboring ras mutations. 
In the clinic these compounds have been major 
disappointments, either as single agents or in 
combination with chemotherapy or radiation [17-18]. In 
hindsight, it seems that there were at least four key areas 
in which our basic understanding of this set of signaling 
pathways and its modification were inadequate to the 
task of developing active and specific therapeutic agents: 
●  Insufficient understanding of the complexity of 
the Ras isoform system in human malignancies. 
●  Incomplete understanding of alternate 
prenylation pathways (e.g. geranylgeranylation) 
when farnesyltransferase is inhibited. 
●  Other effects of the farnesyltransferase 
inhibitors. It is estimated that at least 20 other 
proteins contain the CAAX sequence targeting 
them for farnesylation. The effects of the agents 
developed as FTase inhibitors on these largely 
unknown targets is not known. 
●  Lack of clear understanding as to which 
pathways downstream of ras were critical for its 
effects on radiation sensitivity. Identification of 
such pathways might lead to more selective 
agents for altering radiosensitivity. 
While the search for agents targeting the EGFR 
pathway and those targeting Ras began at about the same 
time, attracted considerable commercial interest, and 
were touted as heralds of the new molecular oncology, 
they have at present led to rather different endpoints. 
Detailed study of what went right and wrong in these two 
approaches may be valuable in improving future efforts 
at targeted drug development. 
Altered Radiation Fractionation in Head and Neck, and 
Lung Cancer 
Prior to the development of chemical agents capable 
of altering the response of cells and tissues to radiation, it H Wagner Jr. Biomed Imaging Interv J 2008; 4(3):e47   4 
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was recognised that alterations in radiation fractionation 
could differentially affect tissues. In classic experiments 
performed in the 1920s Regaud showed that small daily 
doses of radiation could produce sterility in rams while 
preserving skin, whereas unfractionated treatment caused 
desquamation without sterility [19]. This and similar 
observations led to the adoption of daily radiation 
fractionation for most malignancies. In the 1960s and 
1970s data in model animal systems suggested that 
accelerating dose delivery, either by administering larger 
daily fractions (Accelerated fractionation) or keeping the 
fraction size small but giving two or more fractions on 
each treatment day (hyperfractionation), could increase 
local tumour control [20]. Among other possible benefits, 
such a technique could be widely adopted in radiation 
oncology centres throughout the world, required no new 
and potentially expensive technology, and did not require 
infusion of any sensitising or protecting drugs. Clinical 
trials were soon mounted in a variety of disease sites 
with particular interest being placed in ones such as 
tumours of the head and neck where control of 
locoregional disease is closely associated with both 
quality of life and survival. A recent meta-analysis has 
demonstrated that both the hyperfractionated and 
accelerated approaches have produced modest but 
significant improvements in local control, albeit with an 
increase in acute toxicity [21]. 
At about the same time that these trials were being 
implemented, other investigators were exploring the use 
of chemotherapeutic agents such as cisplatin and 
carboplatin as radiation sensitisers. Thus, by the time that 
results of the daily vs. accelerated or hyperfractionated 
radiation trials became mature, the baseline had changed 
and daily radiation as a single modality was no longer 
considered appropriate standard therapy for patients of 
good performance status. A somewhat similar situation 
arose a few years later in trials of daily radiation therapy 
with or without the anti-EGFR monoclonal antibody 
Cetuximab. This lack of coordination of trials resulted in 
the current situation in which we know that any of the 
three approaches, modified fractionation and dose 
escalation, concurrent chemotherapy with cisplatin, or 
concurrent biologic therapy with Cetuximab, is superior 
to conventional daily fractionation as a single modality 
but we do not know whether one of these approaches is 
‘best’ for head and neck cancer patients in general or for 
specific patients.  
It is unfortunate that we lack good correlative 
biologic studies to help individualise the choice of 
sensitiser in specific patients (or to identify those patients 
whose tumours would be controlled with conventional 
therapy and who could be spared the additional toxicities 
associated with more aggressive treatment). Several 
candidates have been suggested and appeared promising 
in small studies, such as proliferative index or potential 
doubling time for fractionation, ERCC1 expression for 
cisplatin, and EFRG expression for Cetuximab. 
Unfortunately it has not been possible, to date, to do 
these assays prospectively across different trials (some 
academic, some industry sponsored), to obtain a better 
ability to select the appropriate fractionation and 
sensitisation strategy on an individual patient basis. 
Potential Pitfalls 
Many factors make extrapolation from the 
laboratory to the clinic difficult and inaccurate. We tend 
to use differing endpoints for laboratory and clinical 
evaluation of agents [22]. Most screening tests for drug-
drug or drug-radiation interactions are based on assessing 
relatively early endpoints. These will assess the effects of 
therapy on the bulk of tumour cells but may tell nothing 
about the effects of this therapy on the rare tumour stem 
cells whose death or survival will determine whether the 
patient enjoys long term local disease control or response 
followed by recurrence. In vitro endpoints such as dye 
exclusion, metabolic activity, apoptosis, and short term 
colony formation and in vivo ones of tumour regression 
and re-growth delay are all assays of differentiated rather 
than stem cells. At present only in vivo assays of local 
control truly address the issue of elimination of stem 
cells. We have only slowly come to realise that tumors 
are not composed simply of tumour cells in great 
numbers, but are organised tissues with stroma, 
vasculature, and tumour cells, and that models 
addressing only a single one of these components will 
rarely be accurate reflections of the clinical situations. 
The recent development and modest success of anti-
vascular agents such as Bevacizumab in combination 
with radiation and chemotherapy attests to the wisdom of 
the late Judah Folkman’s insight of many years ago that 
targeting tumour vasculature might be worthwhile. 
Quality assurance in radiation oncology trials 
The increasing precision in determining 
macroscopic tumour extent as well as radiation dose 
delivery which have come with the development and 
introduction of 4D multimodality imaging and IGRT 
have increased the need for robust quality assurance 
programs in clinical trials as well as routine clinical care. 
The assessment of a potentially radio sensitising drug 
will be confounded when there is substantial 
heterogeneity in the radiation dose delivered to patients 
on a clinical trial designed to evaluate its efficacy. 
During the past decades it has become routine for 
Clinical Cooperative Groups and most commercially 
funded trials to implement rigorous radiation therapy 
quality assurance (RTQA) procedures for credentialing 
radiation therapy facilities prior to their participating in a 
trial and to monitor individual cases. Even with these 
efforts, major variation rates of 5-10% are not 
uncommon, even for relatively straightforward 
treatments (e.g. lateral opposed fields for prophylactic 
cranial irradiation) and the potential for significant 
variation increases with more complex treatments [23-
28].  
Institutional Obstacles  
Pober  et al. have reviewed the obstacles facing 
academic medical centres conducting translational H Wagner Jr. Biomed Imaging Interv J 2008; 4(3):e47   5 
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research [29]. While their examples came primarily from 
the areas of vascular biology and organ transplantation, 
the general principles they identified apply equally well 
to oncology: 
●  Inadequate financial support 
●  Shortage of “translational investigators” 
●  Impediments in the academic culture to 
collaboration 
●  Academic Medical Centre structural 
organisation often hinders collaboration 
●  Regulatory impediments to translation 
●  Absence of mechanisms for facilitation of 
translational research 
So long as collaboration is not actively encouraged 
and incentivised, the cultural, administrative, and 
practical (where to meet, can you get surgeons, medical 
and radiation oncologists, and biochemistry post-docs to 
agree on what a ‘good’ meeting time is) impediments to 
good translational research will make it the exception 
rather than the rule. 
Emerging Applications and Issues for Radiation 
Oncology 
The following are a number of areas of current 
translational research in radiation oncology which 
exemplify some of the foregoing issues. Many others 
could be considered. 
1.  The definition of target volumes for radiation 
therapy is coming to rely increasingly on 
functional as well as the traditional anatomic 
information. Techniques including PET with 
FDG or other tracers, MR spectroscopy, and 
functional MRI give us the potential to image 
such biological parameters as proliferation rate, 
hypoxia, specific gene expression, and 
correlation of anatomy with neurologic function 
(e.g. language). With appropriate image fusion 
this will allow us to sculpt radiation doses to 
volumes biologically deemed appropriate for 
dose escalation [30]. While this is an appealing 
approach there are few data to indicate its 
practicality or correctness and clinical trials will 
need to validate that the imaging indeed 
correlates with function, that complex 
heterogeneously planned dose distributions are 
indeed delivered accurately, and capture 
detailed patterns of failure data to correlate with 
delivered dose. The implications for the RTQA 
process are formidable. 
2.  The development of hypo-fractionated RT for 
NSCLC, pancreatic adenocarcinoma, and other 
malignancies has major interplay with both 
physics and biology. In physics, this has 
involved determination of, and adaptation to, 
real-time tumour motion with respiration and 
cardiac activity, plus development of better 
algorithms for calculating doses with small 
beams and air-tumour tissue heterogeneities. In 
biology, the effect of large fraction size, long 
overall treatment time, hypoxia, and the effects 
of radiation on vasculature as well as tumour 
cells come into play. We are badly in need of 
better methods of assessing tumour response 
and local control in view of the marked fibrotic 
changes developing following such regimens in 
the chest and the frequent intercurrent death of 
patients who have been treated with such 
regimens. 
3.  Observations in patients with malignant 
mesothelioma as well as lung cancer treated 
with complex conformal or IMRT plans in 
which large volumes of lung are treated to low 
doses (e.g. 5Gy during the entire course of 
treatment) have increasingly shown that the 
dose-volume relationships developed for 
patients treated for lung cancer and Hodgkin’s 
disease do not adequately predict pulmonary 
toxicity [31]. The dose distributions outside the 
‘high-dose volume’ with these newer planning 
approaches are very different from those from 
which we had previously developed ‘safe’ dose 
levels, which were based primarily on relatively 
simple APPA and oblique field arrangements. 
The possible role of low dose hypersensitivity 
in lung tissue and the interaction between 
radiation and concurrent chemotherapy will 
also have to be considered as we develop new 
guidelines for tolerance of thoracic irradiation 
[32]. 
4.  To what degree can we accept and widely 
implement (i.e. pay for) new approaches based 
on intermediate endpoints? Or do we need to 
show a clear survival or quality of life benefit 
before adopting ‘promising but unproven’ 
treatments? The use of proton beams to 
supplement or replace photon beams in 
radiation oncology is an example of an 
emerging technology whose true clinical value 
(local control and complication rates) in many 
common malignancies may become known 
only after decades, but where intermediate 
endpoints (radiation dose distributions in 
phantoms) are being used to justify the large 
cost of construction of such facilities and where 
there may be substantial financial rewards for 
early adopters. The physical properties of 
proton beams differ from those of photon 
beams in several ways, particularly in the 
deposition of a large amount of energy at the 
end of their range (the Bragg peak) and very 
rapid dose falloff after this. As a result, the 
relative distributions of dose to target and 
normal tissue volumes from proton beams 
should in theory be superior to those from 
photon beams, leading to a better therapeutic 
ratio. While this is undoubtedly true in theory, 
there is some question as to whether it is 
actually being achieved with present 
implementation of proton beams in which the 
beam modulation is not as advanced as with H Wagner Jr. Biomed Imaging Interv J 2008; 4(3):e47   6 
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photon IMRT. Concerns have also been raised 
about the late carcinogenic effects of neutron 
contamination using the current 
implementations of scattered proton beams. But 
the greater question is whether this in silico 
dosimetric superiority will translate to a 
clinically meaningful difference in outcomes, 
and whether we can move to implement this 
expensive technology as routine treatment for 
common malignancies such as prostate, lung, 
and breast cancers without clinical 
demonstration of benefit. (For paediatric 
malignancies there seems a stronger consensus 
that the ability of proton therapy to reduce 
radiation dose to normal tissues in young 
patients, for whom both growth impairment and 
the risk of second malignancies are major 
concerns with IMRT, will make proton therapy 
the treatment of choice.) For common adult 
malignancies, the Radiation Oncologic 
community is rather sharply divided on this 
question and whether randomised Phase III 
trials are necessary or ethical before this 
technology becomes widely adopted and 
advertised [33-42]. Unfortunately, the issue is 
becoming one in which the scientific concerns 
are being overwhelmed by both uncritical 
enthusiasm that protons are the ‘magic bullet’ 
of radiotherapy and can be easily implemented 
in many facilities and by critics who assume 
that the high costs of current proton facilities 
cannot come down substantially in the future 
[43-45]. Some have argued that the benefits of 
protons are as obvious as those of parachutes, 
another medical therapy adopted without 
randomised trials [46-47]. I would argue that 
comparing proton and photon radiotherapy is 
more like comparing two differing designs of 
parachutes, for which randomised trials might 
not be out of the question. There is also the 
perception by some that there is a lot of money 
to be made by early adopters, before either 
clinical or regulatory reality sinks in. “The 
interest in protons has also been fueled by the 
perception that, although (or, perhaps, because) 
proton facilities are expensive, proton therapy 
can be highly profitable.” [48] 
The Roles of Government and Industry 
Neither laboratory nor clinical research is done in an 
ivory tower or in a clinic isolated from the pressures of 
society. Despite rigorous scientific design and the 
availability of suitable patients, these forces can raise 
significant impediments to the execution of translational 
research. 
The limitation of research on embryonic stem cells 
in the United States during the past decade is one recent 
example of this. Despite strong scientific arguments 
favouring the unrestricted establishment and clinical 
investigation of embryonic derived stem cell lines in 
many areas of medical research, Federal restrictions 
adopted in 2001 forbade the use of Federal research 
funds for stem cell research except with a limited number 
of lines which had already been established. Laboratories 
 
Figure 1  No randomised trials have shown a survival advantage for the use of parachutes when leaving airplanes 
at altitude. (Smith GCS, Pell JP. Parachute use to prevent death and major trauma related to 
gravitational challenge: systematic review of randomised controlled trials. BMJ 2003; 327: 1459-1461) H Wagner Jr. Biomed Imaging Interv J 2008; 4(3):e47   7 
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wishing to work with ‘unauthorised’ lines were required 
to set up redundant parallel mechanisms in the laboratory 
so that equipment purchased with Federal funding for 
approved research would not be used for work with these 
unauthorised lines. Faced with this additional expense, a 
number of programs dropped their stem cell research 
programs, or have had to expend additional time 
searching for alternative private or state funding. 
Numerous scientific bodies and patient advocacy groups 
have argued cogently but to date unsuccessfully against 
these limitations, which appear based more on political 
expediency than any reasoned scientific argument [49]. 
Commercial funding of clinical and translational 
research can also introduce serious constraints on the 
design of clinical trials. This is an understandable result 
of the differing goals of the pharmaceutical or device 
manufacturer, which is to bring an effective product to 
market and benefit its stockholders, and clinical 
researchers. Manufacturers will be reluctant to fund trials 
which run a high risk of showing their product in a less 
than favourable light, either ineffective or toxic, 
particularly before it receives approval from the FDA for 
its primary indication. This has often limited evaluation 
of new agents with potential clinical application as 
radiosensitisers until after their initial approval. A second 
problem arises when it is desired to study two or more 
agents which are being developed by different 
manufacturers. While there may be a strong scientific 
reason to study the combination, such as their inhibiting 
different components of a signaling pathway, 
pharmaceutical companies have been highly reluctant to 
make their developing agents available for such study, 
again largely for fear that toxicities noted for the 
combination may delay approval of their agent. The 
balance between patient protection and speedy 
development of promising new agents is a delicate one 
under the best of circumstances but is complicated 
further by commercial interests. 
One might think that after the successful testing of a 
basic hypothesis in a well-conducted clinical trial, the 
hard work would be over and the newly validated 
therapy would see rapid clinical adoption. Unfortunately, 
this has often not been the case in radiation oncology, 
particularly in trials which have involved altered 
fractionation. Two recent examples in lung cancer are 
good examples of this problem. 
The North American Intergroup trial 0096 compared 
two fractionation schemes, 45Gy/30fx/3wks (BID 
fractionation) and 45 Gy/25fx/5 wks (QD fractionation). 
The BID regimen had been designed based on laboratory 
observations of the minimal shoulder on the radiation 
dose-survival curve for SCLC cell lines and the rapid 
clinical growth of this disease, and had been tested in 
Phase II trials with encouraging results. Mature results of 
this trial published in the New England Journal of 
Medicine showed a statistically significant improvement 
in survival (17% vs. 27%) at five years favouring the 
BID regimen [50]. The BID regimen did cause more 
acute Grade 3 esophagitis but other toxicities were 
similar for the QD and BID regimens. Yet few Radiation 
Oncologists in the US have adopted this as a standard 
regimen, only about 10%. The more popular (but not 
validated in Phase III trials) approach has been to 
increase the total tumour dose to 60-65 Gy using daily 
fractionation. This variation between evidence-based and 
common practice has been recognised by leaders of the 
US clinical cooperative groups for more than five years 
during which there have been several proposals for a 
randomised trial comparing a higher dose QD regimen to 
the 45Gy BID regimen, which have been turned down by 
the NCI on several occasions. We thus remain in a 
position where an evidence-based standard has not been 
adopted by the practice community.  
A similar situation exists in NSCLC. Again, based 
on laboratory data on accelerated repopulation of tumour 
clonogens during a protracted period of fractionated 
radiotherapy, investigators developed accelerated 
fractionation schedules in which fraction size was 
modestly reduced (e.g. to 1.5-1.8 Gy) but two or three 
fractions given per treatment day in order to shorten the 
overall treatment time. The prototype of such regimens 
was the British CHART (Continuous Hyperfractionatd 
Accelerated Radiation Therapy) regimen which treated 
patients for three fractions per day, seven days a week, 
delivering 54 Gy in 36 fractions over 12 treatment days. 
In prospective trials this was shown to be equivalent to 
conventional fractionation for patients with squamous 
cell head and neck cancer and superior to conventional 
fractionation for both local control and overall survival 
for patients with NSCLC. A subsequent trial conducted 
in the US compared a modification of CHART called 
HART, which eliminated the weekend treatments and 
increased total dose to 57.6 Gy in 36 fractions over 2.5 
weeks, to conventional fractionation in patients with 
Stage III NSCLC following two cycles of induction 
carboplatin and paclitaxel and found an improvement in 
median survival of 14.9 to 20.3 months and three-year 
survival from 14% to 34% [51]. These differences 
unfortunately did not reach statistical significance 
because the trial was closed prematurely with only half 
of its planned accrual.  
Macbeth surveyed radiotherapy centres in the UK 
two years after the publication of these results and found 
that only two of 22 were offering CHART to patients 
with lung cancer [52]. Several others were considering 
such implementation but had not yet done so. He 
proposed that three reasons were possible for this lack of 
adoption; the evidence was not believed, the current 
financial climate limited more labour intensive 
fractionation strategies, or that there were not enough 
patients who fit the entry requirements of the CHART 
trials in routine clinical practice to make it worthwhile. 
He further speculated that behind these ‘reasonable’ 
concerns lay three more important reasons not so likely 
to be articulated publically: changing workflow patterns 
and practice culture is difficult, particularly without 
strong financial or academic incentives, the potential 
value of curative radiation therapy for patients with 
NSCLC is undervalued in the oncologic community, and, 
since CHART required no new drugs or radiotherapy H Wagner Jr. Biomed Imaging Interv J 2008; 4(3):e47   8 
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technology to purchase it is without a champion in the 
marketplace. The general failure of altered fractionation 
schemes to make major inroads into clinical practice, 
while not confirming his suspicions, is certainly 
consistent with them. We seem to prefer to radiosensitise 
with cisplatin than with fractionation even when the 
results are similar. 
The development of better targeted and possibly 
individualised therapies raises new questions about the 
marketing of these agents. An agent which can be 
marketed as being effective, albeit only marginally so, 
for all patients with a common disease such as lung 
cancer has a huge potential market. A more selective 
agent with a much greater likelihood of activity but only 
in a select subgroup of patients with the correct pattern 
of molecular targets has, from the standpoint of industry, 
a much smaller potential market, yet similar 
development costs as a ‘me-too’ drug for a common 
indication. This leads to the realistic fear that the 
development and marketing of these effective but niche 
agents may be left to languish, and some would argue 
that the current status of radiolabelled antibody therapy 
for patients with non-Hodgkin’s lymphomas is an early 
example of this phenomenon (53). 
DISCUSSION 
Translational research in its broader sense involves 
not the single step of taking a clever idea from the 
laboratory into clinical trial, but a coordinated series of 
steps back and forth between these two partners, while a 
large number of not-disinterested parties including 
society as a whole, its governmental representatives, 
public and private funding sources, regulatory bodies 
look on from the side.  
Academic conflicts of interest based on pride and 
desire for advancement can be no less compelling and 
distorting of reality than the obvious financial conflicts 
of interest which come with stock ownership or 
commercial funding of research. The recent and ongoing 
controversy over the indirect funding of a major trial 
evaluating CT-based screening for lung cancer by a 
foundation established by the Liggett Group, a major 
tobacco company, illustrates that even the perception of 
possible distortion of research objectives and study 
design can undermine confidence in the results [54]. 
Although some have questioned whether patients are as 
concerned with such conflicts of interest so long as 
active new treatments are developed, it seems highly 
likely that governmental and academic regulatory 
agencies will be even more stringent in keeping a clear 
separation between the commercial funding of medical 
research and its design and publication. Unfortunately, 
with US government funding of cancer research failing 
to match inflation and increasing regulatory costs, 
clinical investigators increasingly find themselves in the 
painful situation of having an exciting variety of agents 
and combinations to test and little money to do so at a 
time when advances in cancer biology give real promise 
of more effective treatments. 
RECOMMENDATIONS 
While it seems an intuitively good idea to bring 
together various specialists involved in the treatment of a 
disease, it has not always been easy to demonstrate 
objectively the benefits of such an approach. Several 
studies of lung cancer treatment before and after the 
organisation of multidisciplinary clinical teams have 
found relatively little change in either intermediate 
endpoints such as time between diagnosis and treatment, 
percent of patients receiving multimodality treatment, or 
more important clinical endpoints such as disease-free or 
overall survival. It may be the case that these were well-
functioning programs before the institution of formal 
teams. But it is also possible that the effective 
implementation of multidisciplinary teams, whether 
among clinicians of varying specialties or the more 
complex admixture of clinicians and basic scientists, 
requires active management to be successful and cannot 
be left to random variation and selection (through grant 
funding) of effective modes of organisation. This may 
indeed be one, probably the only valid, application of 
intelligent design to biology. Yet the application of 
formal management skills and operations research to 
multidisciplinary cancer management is relatively recent. 
Analysis of key milestones in the development of 
drugs which have successfully negotiated the process 
from promising to established has shown how tediously 
long this process has been [10]. Agents were selected as 
successful based on citation frequency. The average lag 
between publication of the first article describing the 
preparation, isolation, or synthesis of a new agent, and 
the publication of the first highly cited article on its 
clinical application was 24 years (interquartile range 14-
44 years). A secondary analysis which considered other 
drugs in the same class found an even longer lag (median 
27 years, interquartile range 21-50 years). The authors 
observed that “Successful translation is demanding and 
takes a lot of effort and time even under the best 
circumstances; making unrealistic promises for quick 
discoveries and cures may damage the credibility of 
science in the eyes of the public.” They recommend 
several steps to improve the present system: 
●  Give proper credit and incentives to high 
quality clinical research including that designed 
to evaluate earlier claims of effectiveness of 
agents. 
●  Encourage collaborations between basic and 
clinical scientists. 
●  Require large, robust randomised clinical trials 
as the criterion of effectiveness of promising 
new therapies. 
●    For common diseases, the research focus 
should be more on developing novel agents and 
technologies rather than demonstrating a real 
but minor benefit from an established therapy. H Wagner Jr. Biomed Imaging Interv J 2008; 4(3):e47   9 
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It is unlikely that an established treatment with 
a major benefit has gone unnoticed. 
An additional constraint on entry of patients to 
clinical trials has been the reluctance of some health 
insurers and other payers to extend coverage for 
treatments deemed experimental, whether or not these 
are part of a formal clinical trial. In some cases not only 
the experimental portion of treatment but the entire 
treatment course has been turned down. Attempts to 
better define the actual costs of participation in clinical 
trials through such efforts as the Cost of Cancer 
Treatment Study may help convince payers that trials 
which can properly identify effective treatments (and 
conversely indicate which treatments are ineffective and 
should not be re-imbursed) may be both scientifically 
valuable and cost effective [55]. The increasing 
willingness of carriers to support Oncotype® testing for 
women with breast cancer, with the understanding that 
the identification of low risk women who do not need 
adjuvant chemotherapy benefits not only the patient but 
saves the insurance carrier the costs of chemotherapy, 
may be one example of the convergence of scientific, 
clinical, and financial objectives. 
The movement of senior investigators from 
university-based to industrial laboratory-based research, 
and back again has increased in recent years, as cultural 
barriers to such participation have faded, grant funding 
become more scarce, and federal limitations on stem cell 
research constrained some lines of investigation except 
with private funding [56]. While such increased 
flexibility may be all to the good it should not be 
forgotten that the need to produce a marketable product 
has the potential to distort the goals and means of 
commercial research just as much as the desire for 
publication and promotion can sully the academic 
research enterprise. Hopefully the incremental and 
ultimately self correcting methods of the scientist, 
whether basic or clinical, will be able to withstand such 
pressures in the long run.  
Fortunately, there is increasing interest in the more 
efficient design and organisation of the basic, 
translational, and clinical biomedical research enterprise. 
This is stimulated both by frustration with the high cost 
and slow progress of the systems which have developed 
in the past as well as recognition that the revolutions in 
molecular biology, synthetic chemistry, medical imaging, 
and medical informatics both mandate and empower new 
approaches to clinical trial design. Considerations range 
from modified statistical design, use of alternative 
endpoints to the old 1 or 2 dimensional response criteria, 
particularly for agents expected to be cytostatic rather 
than cytotoxic, and better engineering of molecular 
specificity for ‘multitargeted’ agents with both activity 
and toxicity in model systems. This creative ferment in 
trial design, along with an increasingly robust 
understanding of tumour biology, provides the scientific 
underpinning for a strong future for translational research 
in oncology. 
Finally, it must be kept in mind that we have not 
completed our task when we have developed an effective 
new therapy, but rather when we have made it available 
to the patients in need of it. Such translation ‘from bench 
to bedside to community’ remains a challenge in much of 
medicine and will require our personal and social 
commitment in the coming decades [67]. 
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